On Tuesday, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) opened lower -4.52% from the last session, before settling in for the closing price of $7.97. Price fluctuations for AUPH have ranged from $4.71 to $10.67 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3969.05% over the past five years. With a float of $128.75 million, this company’s outstanding shares have now reached $143.11 million.
Let’s look at the performance matrix of the company that is accounted for 300 employees. In terms of profitability, gross margin is 87.25%, operating margin of -9.2%, and the pretax margin is -9.14%.
Aurinia Pharmaceuticals Inc (AUPH) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Aurinia Pharmaceuticals Inc is 10.07%, while institutional ownership is 39.69%. The most recent insider transaction that took place on Dec 09 ’24, was worth 4,545,000. In this transaction Director of this company bought 500,000 shares at a rate of $9.09, taking the stock ownership to the 8,429,500 shares. Before that another transaction happened on Dec 06 ’24, when Company’s Director bought 400,000 for $9.01, making the entire transaction worth $3,604,000. This insider now owns 7,929,500 shares in total.
Aurinia Pharmaceuticals Inc (AUPH) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.1 per share during the current fiscal year.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Trading Performance Indicators
Check out the current performance indicators for Aurinia Pharmaceuticals Inc (AUPH). In the past quarter, the stock posted a quick ratio of 5.11. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.94. Likewise, its price to free cash flow for the trailing twelve months is 37.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.16
Technical Analysis of Aurinia Pharmaceuticals Inc (AUPH)
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) saw its 5-day average volume 1.06 million, a negative change from its year-to-date volume of 1.3 million. As of the previous 9 days, the stock’s Stochastic %D was 28.89%. Additionally, its Average True Range was 0.30.
During the past 100 days, Aurinia Pharmaceuticals Inc’s (AUPH) raw stochastic average was set at 24.07%, which indicates a significant increase from 1.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 37.18% in the past 14 days, which was lower than the 43.07% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.58, while its 200-day Moving Average is $6.89. Nevertheless, the first resistance level for the watch stands at $7.81 in the near term. At $8.02, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.12. If the price goes on to break the first support level at $7.50, it is likely to go to the next support level at $7.40. Assuming the price breaks the second support level, the third support level stands at $7.19.
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) Key Stats
There are currently 143,179K shares outstanding in the company with a market cap of 1.09 billion. Presently, the company’s annual sales total 175,510 K according to its annual income of -78,020 K. Last quarter, the company’s sales amounted to 67,770 K and its income totaled 14,350 K.
